OPTIMAL Study

The Optimised Personalised Therapy In Mycobacterium Avium Lung Disease study is being developed by Professor Gerry Davies, Professor of Infection Pharmacology at the University of Liverpool, in conjunction with NTM Network UK. It aims to determine the relative activity of combinations of common agents used for the treatment of Mycobacterium Avium complex (MAC), to explore early biomarkers of response to therapy for MAC, and to evaluate pharmacokinetic/pharmacodynamic relationships of key drugs used in the treatment of MAC.